Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-07-24
1999-06-22
Rose, Shep K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546212, A61K 31445
Patent
active
059143339
ABSTRACT:
The present invention relates to a method for the treatment of psychotic disorders.
REFERENCES:
patent: 4383999 (1983-05-01), Bondinell et al.
patent: 5354760 (1994-10-01), Petersen et al.
patent: 5660861 (1997-08-01), Jao et al.
Mosconi et al Int. J. Clin. Pharmacol. Res. 13/6:331-334 New Anxiolytics in Development, 1993.
Dodrill et al (II) Epilepsia 39(1): 33-42 Effects of Tiagabine Monotherapy on Abilities Adjustment and Need, 1998.
Mohler Schweizerische Rundschau fur Medizin/Praxis:87/6:186-190, 1998.
Beneficial Results of Tiagabine Therapy in Patients with Psychiatric History Kraus et al Epilepsia 38 Suppl 8 106, Dec. 7-10, 1997.
Dodrill et al I Neurology 46 (2 Suppl) A277 Changes in Mental Abilities and Adjustment with Conversion to Tiagabine Monotherapy, Mar. 23-30, 1996.
Nielson et al Eur. J. Pharmacol. 196/3:257-266 Characterization of Tiagabine (No. 328) A New Potent and Selective GABA Uptake Inhibitor in Diazepam or Amphetamine Rats, 1991.
Esq. Reza Green
Novo Nordisk A S
Rose Shep K.
Zelson Esq. Steve T.
LandOfFree
Treatment of psychotic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of psychotic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of psychotic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1708342